Bone Marrow Mesenchymal Stem Cells Affect The Cell Cycle Arrest Effect Of Genotoxic Agents On Acute Lymphocytic Leukemia Cells Via p21 Down-Regulation

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4988-4988
Author(s):  
Yiran Zhang ◽  
Kaimin Hu ◽  
Yongxian Hu ◽  
Binsheng Wang ◽  
He Huang

Abstract The recurrence rate of acute lymphocytic leukemia (ALL) in adult is high, and the five-year survival rate of recurrent patients is as low as 7%. Increasing evidence indicates that bone marrow mesenchymal stem cell (BMSC), which is a pivotal component of the bone marrow microenvironment, can enhance the survival and drug resistance of ALL cells, which is a reason for the high recurrence rate of ALL in adult. However, whether BMSCs promote or block the cell-cycle and proliferation of leukemia is indefinite, and whether BMSCs affects the the cell cycle arrest effect of genotoxic agents on ALL cells is unclear. In this study, human BMSCs was obtained from normal bone marrow donors, and ALL cell line Reh was cultured with or without BMSCs in the presence or absence of etoposide (VP16) or idarubicin (IDA). MLN4924, the inhibitor of SCF complex, was used to induce the high expression of cell-cycle inhibitor p21. The proliferation of ALL cells was detected by CCK-8 kit and cell cycle was analyzed by flow cytometry with PI staining. The protein expression of ALL cells was determined by western blot and the mRNA expression was detected by qRT-PCR. The results indicated that BMSCs affected the cell cycle arrest effect of genotoxic agents on ALL cells. In the absence of drugs, BMSCs had no significant effect on the cell-cycle of Reh cells. Under the treatment of VP16, the S phase ratio of Reh cultured with BMSCs was higher than Reh cultured alone (10.893±1.077% and 6.842±0.652% respectively, p<0.05), the G2/M phase ratio of Reh cultured with BMSCs was lower than Reh cultured alone (25.812±1.720% and 38.818±3.508% respectively, p<0.05). Under the treatment of IDA, the S phase ratio of Reh cultured with BMSCs was higher than Reh cultured alone (58.720±5.765% and 45.519±7.886% respectively, p<0.05), the G2/M phase ratio of Reh cultured with BMSCs was lower than Reh cultured alone (1.888±0.809% and 6.449±0.325% respectively, p<0.05). At both protein and mRNA level, treatment of VP16 or IDA induced the expression of p21 in Reh cells, while BMSCs down-regulated its expression. MLN4924-induced p21 high expression in Reh cells eliminated the cell-cycle promotion effect of BMSCs on Reh cells under the treatment of genotoxic agents, which confirmed that BMSCs affect the cell cycle arrest effect of genotoxic agents on ALL cells via p21 down-regulation. Moreover, in the presence of VP16 or IDA, BMSCs reduced the p53 mRNA expression and increase the c-myc mRNA expression in Reh cells, and BMSCs also up-regulated the protein expression of p-Erk and β-catenin in Reh cells. Since p53 is the major transcription factor of p21 and c-myc is the transcription inhibitor of p21, our results suggested that the BMSCs induced down-regulation of p21 in ALL cells might be through down-regulation of p53 and activation of Wnt/β-catenin/c-myc and erk/c-myc pathways. In conclusion, the present study indicates that BMSCs affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation. This finding suggests that targeting the effect of microenvironment on leukemia might be a novel approach for ALL therapy. Disclosures: No relevant conflicts of interest to declare.

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4083-4083 ◽  
Author(s):  
Xingyi Kuang ◽  
Jie Xiong ◽  
Weili Wang ◽  
Xinyao Li ◽  
Tingting Lu ◽  
...  

Abstract The serine/threonine PIM protein kinases are critical regulators of turmorigenesis in mutiple hematologic malignancies and solid cancers. We used real-time PCR to detect the expression of PIM in B-cell acute lymphocytic leukemia (B-ALL) patients, and found the expression of PIM in B-ALL patients was significantly higher than that in normal controls. SMI-4a is a pan-PIM small molecule inhibitor, and this agent exhibits demonstrable preclinical antitumour activity in a wide range of hematologic malignant cell lines. To further explore the effect of SMI-4a on B-ALL cells, B-ALL cell lines CCRF-SB and Sup-B15 were treated with this small molecule inhibitor, and the results showed that SMI-4a inhibited B-ALL cell proliferation in a dose- and time-dependent manner. Moreover, SMI-4a significantly promoted B-ALL cell apoptosis and caused cell cycle arrest in the G0/G1 phase. The results of Western blot showed that SMI-4a increased the expression of Caspase-3, Caspase-9, Bax and P21, and decreased the expression of Bcl-2 and CDK4. Furthermore, we found that SMI-4a significantly inhibits the activation of the JAK2/STAT3 pathway and HO-1 interferes with the JAK2/STAT3 pathway to inhibit SMI-4a-induced ALL cell apoptosis. Finally, xenograft experiments in NOD/SCID mice were operated to investigate the potential role of SMI-4a in B-ALL tumorigenesis in vivo. To observe the effect of SMI-4a on tumor growth in vivo, NOD/SCID mice were transplanted with B-ALL devied cells, and the tumor-bearing mice were intraperitoneally injected with saline and SMI-4a, respectively. As a result, tretment with SMI-4a resulted in a significant inhibition on tumor growth. In addition, PIM inhibtor obviously reduced the volume and weight of B-ALL cell-derived tumors. TUNEL assay revealed the proportion of apoptotic cells was higher in the SMI-4a-treated group than in the control group. Taken together, our data showed PIM inhibitor (SMI-4a) significantly inhibits the growth of B-ALL cells in vitro and in vivo and promotes apoptosis and cell cycle arrest. This suppressive effect is mediated partly through inhibiting the JAK2/STAT3 pathway activation. Disclosures No relevant conflicts of interest to declare.


2014 ◽  
Vol 84 (5) ◽  
pp. 578-584 ◽  
Author(s):  
Hongjian Yang ◽  
Xiangming He ◽  
Yabing Zheng ◽  
Weiliang Feng ◽  
Xianghou Xia ◽  
...  

Nutrients ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 488 ◽  
Author(s):  
Yeong-Seon Won ◽  
Kwon-Il Seo

Prostate cancer is the most common cancer in Western countries. Recently, Asian countries are being affected by Western habits, which have had an important role in the rapid increase in cancer incidence. Sanggenol L (San L) is a natural flavonoid present in the root barks of Morus alba, which induces anti-cancer activities in ovarian cancer cells. However, the molecular and cellular mechanisms of the effects of sanggenol L on human prostate cancer cells have not been elucidated. In this study, we investigated whether sanggenol L exerts anti-cancer activity in human prostate cancer cells via apoptosis and cell cycle arrest. Sanggenol L induced caspase-dependent apoptosis (up-regulation of PARP and Bax or down-regulation of procaspase-3, -8, -9, Bid, and Bcl-2), induction of caspase-independent apoptosis (up-regulation of AIF and Endo G on cytosol), suppression of cell cycle (down-regulation of CDK1/2, CDK4, CDK6, cyclin D1, cyclin E, cyclin A, and cyclin B1 or up-regulation of p53 and p21), and inhibition of PI3K/Akt/mTOR signaling (down-regulation of PI3K, p-Akt, and p-mTOR) in prostate cancer cells. These results suggest the induction of apoptosis via suppression of PI3K/Akt/mTOR signaling and cell cycle arrest via activation of p53 in response to sanggenol L in prostate cancer cells.


2010 ◽  
Vol 290 (1) ◽  
pp. 96-103 ◽  
Author(s):  
Hyun Ju Kwon ◽  
Yun Kyung Hong ◽  
Cheol Park ◽  
Yung Hyun Choi ◽  
Hee Jung Yun ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document